What Peyronie's Disease Is

Peyronie's disease (PD) is a wound-healing disorder of the tunica albuginea — the tough collagen sheath around the erectile bodies. In genetically predisposed men, penile trauma triggers abnormal scarring: instead of resolving, the scar tissue keeps building. The result is a fibrous plaque that restricts normal expansion during erection, causing curvature, deformity, and often pain (Kadioglu 2011). Important: only 29% of patients recall a specific traumatic event (Paulis 2024) — most PD occurs without remembered trauma. If you don't remember an injury, that does NOT rule out PD.

How common: 3-9% of adult men. Likely underreported because men are reluctant to seek care. 24% of patients are ≤40 years old — younger than previously thought (Paulis 2024, n=564). Note: PD doesn't always present with visible curvature — the CUA guideline (Bella 2018) describes atypical PD (penile septal scar) causing ED and pain WITHOUT palpable deformity or curvature.

Two phases:

• Acute (active): Progressive deformity — curvature and/or plaque still evolving. Pain may or may not be present. There is no fixed timeline (ICSM 2024 explicitly: "no universally agreed-upon definition of the acute phase"). The old "12-18 months" framing has been abandoned by the most current guideline. Active phase is defined by whether deformity is still progressing, not by how many months have passed. Paulis 2024 documented active disease at 22-26 months — with pain already resolved but curvature still worsening.
• Stable (chronic): Curvature stops changing (no change for ≥3 months). Pain may still be present in stable phase — "pain with erection may be present due to torque or stretch on the penile scar" (ICSM 2024). Pain resolution alone does NOT confirm stability.
• Surgical eligibility requires stable phase for at least 6 months (ICSM 2024 Rec #18) — this is a higher threshold than the 3-month phase definition.
• Penile shortening is the most common deformity (88.2%, Paulis 2024) — more than 70% of patients report shortening BEFORE any surgery (Osmonov ESSM 2022). The disease causes the shortening, not surgery.
• Multifocal plaque occurs in 16.1% (Paulis 2024).

The question for YOUR situation is not "how many months has it been?" It's: "is your curvature still getting worse?" Your answer — yes, noticeably worse in the last month — confirms active disease by the most current definition. You are not "in transition." You are in active phase.

Your Doppler Findings (March 19, 2026)

Note on Lamb's verbal "reduced blood flow" comment: The written report shows all vascular parameters as NORMAL. If Lamb said something different verbally, ask the second-opinion urologist to review the actual Doppler images — not just the report — to resolve the discrepancy. (See Evidence Reference §1.4)

The Psychological Reality

This is hard. The research confirms it:

• 88.4% of active-phase PD patients presenting to a specialist andrology clinic reported significant anxiety (GAD-7 >9, Paulis 2024 n=564 — note: 99.1% Caucasian, Italian single-center, specialist-seeking high-bother population; community rates and other demographics may differ)
• Rates of depression vary by instrument and population: 27% on CES-D ≥16 (Punjani 2021, n=408); 47% as reported by Nelson and cited in CUA guidelines (Bella 2018 — instrument not specified in guideline text); 57.6% on PHQ-9 >9 in an active-phase specialist clinic (Paulis 2024, n=564). The range (27-58%) reflects different instruments, thresholds, and populations — not contradictory findings.
• Depression is driven by bother and self-image, NOT by curvature degree — IIEF does not significantly correlate with curvature severity (p=0.359), plaque volume (p=0.09), or disease duration (p=0.554) (Paulis 2024, Table 7). This independently confirms Goldstein 2017's finding that improvement tracks with reduced bother, not mechanical correction.
• Being partnered is protective against depression (OR 0.42, Punjani 2021)
• 56.4% of PD patients with ED had ED BEFORE developing PD (Paulis 2024) — ED is not always PD-caused. If your ED partially predates the PD, treating the PD alone may not fully resolve it.
• Psychotherapy is clinically recommended: Paulis 2024 (n=564) concludes that "psychotherapy should be integrated into the treatment of PD patients to enhance quality of life and discourage them from discontinuing ongoing medical therapies." This isn't optional emotional support — it helps people stay on treatment. Ask the second-opinion urologist about mental health referral.
• Partners are affected too: 75% of female partners of men with PD met criteria for sexual dysfunction before treatment (Goldstein 2017)

This is the norm for PD patients, not a personal weakness. Treatment — even modest improvement — reduces bother and restores sense of agency, which drives quality-of-life improvement independently of curvature change. (See Evidence Reference §1.6)

The Evidence Hierarchy — What Actually Works

The evidence hierarchy puts CCH and traction at the top — verapamil isn't on the list at all.

Tier 1: Strong controlled evidence

CCH (Xiaflex) — The only FDA-approved PD injection. Two large double-blind RCTs (IMPRESS, n=832) plus two meta-analyses confirm significant curvature improvement. (Detailed in Part 3A)

Tier 2: Positive controlled evidence, but guidelines oppose routine use

Hyaluronic Acid (HA) — Two double-blind RCTs show it outperforms verapamil. Zero adverse events. But EAU 2026 and ICSM 2026 both recommend AGAINST routine use outside clinical trials. Approved only in Italy. (Detailed in Part 3B)

Tier 3: Supported by RCT, immediately actionable

RestoreX traction — RCT (n=100): -11.7° curvature improvement at just 30-90 min/day. Can start NOW — no prescription needed, no phase requirement. ICSM 2024 upgraded traction to Conditional Recommendation with Moderate Quality of Evidence — the most current major-society endorsement. (Detailed in Part 3C)

Tier 4: Reasonable adjunct, limited curvature evidence

Tadalafil daily (5 mg) — Does NOT prevent curvature progression (Durukan 2024, P=.08). MAY shorten pain duration (9.1 vs 12.2 months, P=.04). Supports ED and penile oxygenation. Part of the Mayo Clinic oral protocol: pentoxifylline + L-citrulline + tadalafil. (See Evidence Reference §2.2)

Tier 5: No controlled curvature evidence

Verapamil injection — Your current treatment. The only double-blind RCT (Favilla 2017, n=140) showed exactly zero curvature change. Every controlled trial is negative. Positive results appear only in uncontrolled studies. (Detailed in Part 3D)

Tier 6: Surgical options (if conservative treatment fails)

Plication, grafting, prosthesis — Gold standard for stable-phase PD with significant curvature. Plication does NOT cause additional length loss beyond what PD itself produces (Garaffa 2024, n=91, abstract only). Perception gap: Hudak found 84% had no measurable decrease in stretched penile length, but 78% perceived length reduction — the gap between measurement and perception is large and important for surgical counseling. Prior CCH does NOT increase surgical complications. Important expectations: Grafting curvature recurrence: 50-78% in longer-term follow-up (Osmonov ESSM 2022). Even with prosthesis, >25% of patients were dissatisfied with straightness despite achieving <20° residual curvature in the OR — "functionally straight" may not match patient expectations (Ziegelmann 2020). Note: surgical ED outcome data across most studies uses the IIEF questionnaire, which has not been validated for PD (Osmonov 2022) — ED rates are indicative, not precise. (See Evidence Reference §2.6)

What You Can Do RIGHT NOW — Before the Appointment

1. Order a RestoreX device. Available online. Start at 30 min/day. The RCT showed -11.7° at 30-90 min/day for 3 months — the lowest time burden of any traction device studied (Ziegelmann 2019).

2. Consider starting tadalafil 5 mg daily (ask your PCP or current urologist). Supports penile oxygenation and ED independently of PD treatment. Part of the Mayo oral protocol.

3. Stop expecting results from 3-month verapamil. The evidence doesn't support curvature improvement at ANY interval, and your interval has no published precedent.

Part 3A — CCH (Xiaflex): The Strongest Evidence

What it is: A bacterial enzyme that breaks down the collagen in PD plaques. The only FDA-approved injection for PD.

How well it works:

• IMPRESS trials (n=832): 34% curvature improvement vs 18% placebo. The AUA guideline calls this "a modest difference of 7.7°" — honest framing (Gelbard 2013).

• Pooled across 11 studies (n=1,480): 35% improvement with zero heterogeneity — remarkably consistent (Zhang 2022).

• Less than half respond by strict criteria: In IMPRESS phase III, only 46% met the composite responder definition (≥20% curvature improvement + >1-point PDQ bother reduction). Flores 2022 (n=114, different metric): 44% improved, 39% no change, 17% worsened. Both measures converge: fewer than half of CCH patients achieve clinically meaningful improvement.

• Important: These rates are from pre-selected favorable populations — IMPRESS excluded hourglass deformity, ED, ventral curvature, and significant calcification. Real-world patients are less pre-selected.

• Real-world gap: Post-approval community data (Tsambarlis, per Ziegelmann 2020, n=45) found only 5.4° mean improvement vs IMPRESS's 17° — trial results don't always translate to community practice.

• ⊕ NEW: Trost-protocol outcomes (Cahill 2025, n=826): With aggressive modeling + 0.9mg dose + RestoreX, median improvement was 27.5-32.5° — nearly double IMPRESS. These are NOT standard CCH results — they require the specific Trost protocol. ⚠️ Triple COI: Trost is RestoreX inventor + PathRight part-owner + Endo-funded. Confound: 98% used RestoreX, insufficient non-use power to isolate its independent effect.

For YOUR specific case:

• Your 40° dorsal curvature is in the best-responding category: 50% median improvement for dorsal vs 33.6% ventral (Lumbiganon 2025, n=292). Lateral curvature is 11° worse (Cahill 2025, multivariate P<.001). You're in the favorable group.
• Baseline curvature predicts response: per 10° increase, OR 1.33 for improvement (Flores 2022). Your 40° is favorable.
• ⊕ Your volume-loss deformity (thinning upper 1/3) is FAVORABLE for CCH response. Cahill 2025 (n=826, multivariate P=.02) found moderate/severe hourglass/indentation predicts 3-10° MORE improvement than none/mild. This contradicts the prior assumption that hourglass limits CCH candidacy. Your self-noticed thinning maps onto the best-responding subgroup.
• Adding RestoreX traction: associated with 19.5° greater improvement in multivariate analysis (Cahill 2025, P=.02), and 6.9× more likely to achieve ≥20° improvement vs CCH alone (Alom 2019, abstract). RestoreX was the strongest predictor of all factors assessed — though confounded with concurrent protocol changes.
• Active phase is NOT a barrier: Cahill 2025 (P=.48, NS) and Cocci 2020 (-19.3°, n=74) both support CCH in active disease. Your active progression does not rule out CCH.

The protocol:

• Standard (IMPRESS): 4 cycles × 2 injections = 8 injections over 24 weeks. Cost: ~$15,000-18,000 total, but out-of-pocket <$300/cycle — you've maxed your OOP.
• Shortened (Ralph): 3 injections at 4-week intervals. Similar efficacy, lower cost (Capece 2018, n=135).
• Cycle-2 decision point: If no improvement after 4 injections, continuing offers minimal additional benefit (Flores 2022, Anaissie 2017). Don't keep going if it's not working.
• Modeling is NOT optional. CCH without structured modeling produces minimal benefit. The placebo arm in IMPRESS improved by 9.3° — likely FROM modeling alone.

Side effects:

• Expected (nearly universal): 84.2% of CCH patients had at least one adverse event vs 36.3% placebo (IMPRESS, per AUA guideline Nehra 2015). Bruising (60-93%), pain (34%), swelling (30%). Most mild/moderate, resolve within 14 days.
• Serious (rare): penile fracture — IMPRESS: 0.36% (3/832). Lumbiganon: 1.4% (4/292 with intensive 3×/day modeling). Real but rare.
• No sexual activity for 2 weeks after each injection cycle.

Guideline status: EAU gives the strongest endorsement (Level 1b, Strong). AUA, CUA, ISSM all support. CCH is withdrawn outside the USA — US-only availability.

(See Evidence Reference §3A for full study-by-study data)

Part 3B — Hyaluronic Acid (HA): Positive Data, Guideline Opposition

What it is: A naturally occurring molecule in connective tissue. Anti-inflammatory and anti-fibrotic. NOT FDA-approved for PD.

How well it works:

• Favilla 2017 (double-blind RCT, n=140): HA -4.6° vs verapamil 0.0° (P<0.001). The definitive head-to-head.
• Abdel Fattah 2024 (double-blind RCT, n=42): HA -9.4° vs verapamil -5.4° (P=.038).
• Cilio 2024 (stable phase, n=62): -12.4° with multimodal mechanics (vacuum + stretching + modeling).

The critical caveat: Despite this positive RCT data, both the EAU (2026) and ICSM (2026) recommend AGAINST routine HA use outside clinical trials. These guideline committees reviewed the same papers we cite here. Their judgment: the evidence base (small samples, no placebo-only trials of HA alone, heterogeneous protocols) is not yet sufficient for routine recommendation. Only approved for PD in Italy.

What this means for you: Pursuing HA means going against current major guidelines. That's a legitimate choice — guidelines aren't mandates — but your urologist should be able to articulate why they diverge from the recommendations. If they can't, that's a flag.

Safety: The cleanest profile of any PD injection. Zero significant adverse events across ALL studies (>600 patients). No fracture risk. No bruising. (See Evidence Reference §3B)

Part 3C — RestoreX Traction: Start Now

What it is: A penile traction device with a counter-bending mechanism. The only traction device with positive RCT data at a practical time commitment.

How well it works:

• Ziegelmann 2019 RCT (n=100): -11.7° curvature improvement vs +1.3° in controls. +1.5 cm length gain. 30-90 min/day for 3 months (Ziegelmann 2019, abstract).
• When combined with CCH: 6.9× more likely to achieve ≥20° improvement vs CCH alone (Alom 2019, abstract).
• First study showing benefit at <3 hours daily — prior devices required 3-8 hours.

Why start now:

• No prescription needed.
• No phase requirement — works in both acute and stable.
• Independent benefit whether or not you pursue CCH or HA.
• The counter-bending mechanism specifically targets curvature correction — conventional traction devices did NOT show the same CCH-enhancement effect.

(See Evidence Reference §3C)

Part 3D — Verapamil: What You're Currently On

The evidence:

• Only double-blind RCT (Favilla 2017, n=140): Exactly zero curvature change (0.00° ± 0.00).
• Every controlled trial is negative. Positive results appear ONLY in uncontrolled studies.
• Your 3-month interval: no published protocol uses this. Standard is biweekly to monthly.

Why your urologist might have chosen it: Cost ($60/year vs $15,000+ for CCH), availability, safety, and ability to use in acute phase. These are practical advantages. They don't overcome the absence of controlled curvature efficacy.

Guideline status: AUA says "may consider" (Conditional, Grade C) but calls the evidence "weak" and notes "the availability of other treatments that are clearly more effective." EAU recommends AGAINST (Level 4). CUA recommends (Level 3, Grade C — outlier, practice-based: "more than two decades of experience," not controlled evidence). ICSM: Conditional, "may reduce curvature in SOME patients." (See Evidence Reference §3D)

Decision Matrix — Updated for Active Progression

YOUR CURRENT STATE: Active progression. You report visible curvature worsening in the last month. Combined with pain reduction (8-9 → 2-3), this tells us: your disease is biologically evolving. Pain reduction does NOT equal curvature stability. You are NOT in stable phase.

How to frame the appointment: This is NOT a "second opinion." This is: "My current treatment is not working. My disease is actively progressing on verapamil at 3-month intervals — a protocol with no published evidence base. I need a new treatment plan."

Treatment options for YOUR current (active) phase

What the appointment will clarify

What You Can Do TODAY — No Doctor Needed

1. Order a RestoreX device and start at 30 min/day. RCT-supported: -11.7° at 30-90 min/day. No prescription, no phase requirement. Your disease is actively progressing — don't wait.
2. Start L-citrulline 750mg twice daily (OTC supplement). One component of the Mayo Clinic oral PD protocol (Ziegelmann 2020). The prescription components (pentoxifylline, tadalafil) come from the second-opinion urologist.
3. NSAIDs for residual erection pain (OTC). Guideline-supported for active-phase PD. Won't fix curvature but addresses comfort.
4. Document your curvature — take erect photographs over the next several days. Multiple angles, consistent lighting. This becomes evidence of progression at the second opinion (vs March 40° baseline).
5. Request your full medical records from Lamb's office — chart notes from every visit, physical exam documentation, AND the Doppler scan images (not just the written report). These are your records (HIPAA-guaranteed). The second-opinion urologist needs the complete picture, including what WASN'T assessed.
6. Stop expecting results from 3-month verapamil. Your disease is progressing on it. The evidence never supported it. Don't push the current doctor for the cream — topical verapamil doesn't penetrate the tunica albuginea (Martin et al.) and all four major guidelines recommend against it.

Red Flags in the Urologist's Response

Green Flags

• They perform in-office curvature assessment with pharmacological erection + goniometer (only 60% of urologists do this — Brant 2023, n=145 from 12,018 surveyed)
• They assess for volume-loss deformities without being asked
• They know what Favilla 2017 showed
• They discuss CCH with RestoreX as a combination
• They are fellowship-trained in andrology/sexual medicine (only 19% of PD-treating urologists are — fellowship-trained specialists are significantly more likely to use evidence-based treatments across every measured category)

Why fellowship training matters: Brant 2023 found that 81% of urologists treating PD have NO fellowship in andrology/sexual medicine. Every evidence-based practice measured — CCH use, traction, in-office assessment, duplex ultrasound — was significantly more common in fellowship-trained physicians (P<0.005 for all). Even among urologists who say they follow AUA guidelines, 21% still use explicitly discouraged treatments. The 21% figure likely underestimates the real gap: the survey had a 1.2% response rate, and evidence-unaware urologists are least likely to respond to evidence-practice surveys. Younger urologists (<20 years practice) are more evidence-based than older colleagues across CCH, NSAIDs, and traction use.

Where to Find the Evidence

Every claim in this document traces to a specific study in the Evidence Reference (Document B). When a claim cites (Author Year), look it up in the Evidence Reference for: study design, sample size, methodology, exact numbers, and limitations.

The Evidence Reference is organized to match this document section-by-section:

• §1 = Part 1 (Your condition)
• §2 = Part 2 (Treatment landscape)
• §3A-D = Part 3 (Deep dive drugs)
• §4 = Part 4 (Decision matrix)
• §5 = Part 5 (Red/green flags)